|
1
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr and Wu YL: Paz-Ares: Lung cancer: current
therapies and new targeted treatments. 389:299–311. 2017.
|
|
3
|
Giaccone G: The potential of
antiangiogenic therapy in non-small cell lung cancer. Clin Cancer
Res. 13:1961–1970. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S,
Feng J, He J, Han B, Wang J, et al: BEYOND: A randomized,
double-blind, placebo-controlled, multicenter, phase III study of
First-Line carboplatin/paclitaxel plus bevacizumab or placebo in
chinese patients with advanced or recurrent nonsquamous
non-small-cell lung cancer. J Clin Oncol. 33:2197–2204. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Galetta D, Cinieri S, Pisconti S, Gebbia
V, Morabito A, Borsellino N, Maiello E, Febbraro A, Catino A, Rizzo
P, et al: Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed
Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance
Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo
Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial.
Clin Lung Cancer. 16:262–273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seto T, Kato T, Nishio M, Goto K, Atagi S,
Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al:
Erlotinib alone or with bevacizumab as first-line therapy in
patients with advanced non-squamous non-small-cell lung cancer
harbouring EGFR mutations (JO25567): An open-label, randomised,
multicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Niho S, Kunitoh H, Nokihara H, Horai T,
Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K,
et al JO19907 Study Group, : Randomized phase II study of
first-line carboplatin-paclitaxel with or without bevacizumab in
Japanese patients with advanced non-squamous non-small-cell lung
cancer. Lung Cancer. 76:362–367. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Herbst RS, Ansari R, Bustin F, Flynn P,
Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P and Hainsworth
J: Efficacy of bevacizumab plus erlotinib versus erlotinib alone in
advanced non-small-cell lung cancer after failure of standard
first-line chemotherapy (BeTa): A double-blind, placebo-controlled,
phase 3 trial. Lancet. 377:1846–1854. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reck M, von Pawel J, Zatloukal P, Ramlau
R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et
al: Phase III trial of cisplatin plus gemcitabine with either
placebo or bevacizumab as first-line therapy for nonsquamous
non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vacca A, Iurlaro M, Ribatti D, Minischetti
M, Nico B, Ria R, Pellegrino A and Dammacco F: Antiangiogenesis is
produced by nontoxic doses of vinblastine. Blood. 94:4143–4155.
1999.PubMed/NCBI
|
|
12
|
Kruczynski A, Poli M, Dossi R, Chazottes
E, Berrichon G, Ricome C, Giavazzi R, Hill BT and Taraboletti G:
Anti-angiogenic, vascular-disrupting and anti-metastatic activities
of vinflunine, the latest vinca alkaloid in clinical development.
Eur J Cancer. 42:2821–2832. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gridelli C, Perrone F, Gallo C, Cigolari
S, Rossi A, Piantedosi F, Barbera S, Ferraù F, Piazza E, Rosetti F,
et al MILES Investigators, : Chemotherapy for elderly patients with
advanced non-small-cell lung cancer: The Multicenter Italian Lung
Cancer in the Elderly Study (MILES) phase III randomized trial. J
Natl Cancer Inst. 95:362–372. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
No authors listed: Effects of vinorelbine
on quality of life and survival of elderly patientswith advanced
non-small-cell lung cancer. The Elderly Lung Cancer
VinorelbineItalian Study Group. J Natl Cancer Inst. 91:66–72. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC, et al: New guidelines to evaluate the
response to treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Institute of the
United States, National Cancer Institute of Canada. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar
|
|
16
|
Weiss JM, Villaruz LC, Socinski MA,
Ivanova A, Grilley-Olson J, Dhruva N and Stinchcombe TE: A
single-arm phase II trial of pazopanib in patients with advanced
non-small cell lung cancer with non-squamons histology with disease
progression on bevacizumab containing therapy. Lung Cancer.
86:288–290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Powell SF, Beitinjaneh A, Tessema M, Bliss
RL, Kratzke RA, Leach J, Dudek AZ and Phase II: Phase II study of
topotecan and bevacizumab in advanced, refractory non-small-cell
lung cancer. Clin Lung Cancer. 14:495–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kubota T, Okano Y, Sakai M, Takaoka M,
Tsukuda T, Anabuki K, Kawase S, Miyamoto S, Ohnishi H, Hatakeyama
N, et al: Carboplatin plus Weekly Paclitaxel with Bevacizumab for
First-line Treatment of Non-small Cell Lung Cancer. Anticancer Res.
36:307–312. 2016.PubMed/NCBI
|
|
19
|
Ohyanagi F, Yanagitani N, Kudo K, Kawano
Y, Sakatani T, Tanimoto A, Nishizawa H, Horiike A, Hagiwara S,
Horai T, et al: Phase II study of docetaxel-plus-bevacizumab
combination therapy in patients previously treated for advanced
non-squamous non-small cell lung cancer. Anticancer Res.
34:5153–5158. 2014.PubMed/NCBI
|
|
20
|
Herbst RS, O'Neill VJ, Fehrenbacher L,
Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M and Sandler
A: Phase II study of efficacy and safety of bevacizumab in
combination with chemotherapy or erlotinib compared with
chemotherapy alone for treatment of recurrent or refractory non
small-cell lung cancer. J Clin Oncol. 25:4743–4750. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kosmas C, Tsavaris N, Panopoulos C,
Vadiaka M, Stavroyianni N, Kourelis T, Malamos N, Antonopoulos M
and Kalofonos HP: Gemcitabine and vinorelbine as second-line
therapy in non-small-cell lung cancer after prior treatment with
taxane+platinum-based regimens. Eur J Cancer. 37:972–978. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshida M, Muro K, Tsuji A, Hamamoto Y,
Yoshino T, Yoshida K, Shirao K, Miyata Y, Takahari D, Takahashi T,
et al: Combination chemotherapy with bevacizumab and S-1 for
elderly patients with metastatic colorectal cancer (BASIC trial).
Eur J Cancer. 51:935–941. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pujol JL, Lavole A, Quoix E, Molinier O,
Souquet PJF, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, et al:
French Cooperative Thoracic Intergroup (IFCT); FrenchCooperative
Thoracic Intergroup IFCT. Randomized phase II–III study
ofbevacizumab in combination with chemotherapy in previously
untreated extensivesmall-cell lung cancer: Results from the
IFCT-0802 trial. Ann Oncol. 26:908–914. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wildiers H, Guetens G, De Boeck G,
Verbeken E, Landuyt B, Landuyt W, de Bruijn EA and van Oosterom AT:
Effect of antivascular endothelial growth factor treatment on the
intratumoral uptake of CPT-11. Br J Cancer. 88:1979–1986. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dickson PV, Hamner JB, Sims TL, Fraga CH,
Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF and
Davidoff AM: Bevacizumab-induced transient remodeling of the
vasculature in neuroblastoma xenografts results in improved
delivery and efficacy of systemically administered chemotherapy.
Clin Cancer Res. 13:3942–3950. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gridelli C, Bennouna J, de Castro J,
Dingemans AM, Griesinger F, Grossi F, Rossi A, Thatcher N, Wong EK
and Langer C: Randomized phase IIIb trial evaluating the
continuation of bevacizumab beyond disease progression in patients
with advanced non-squamous non-small-cell lung cancer after
first-line treatment with bevacizumab plus platinum-based
chemotherapy: Treatment rationale and protocol dynamics of the
AvaALL (MO22097) trial. Clin Lung Cancer. 12:407–411. 2011.
View Article : Google Scholar : PubMed/NCBI
|
